Advertisement
Screener

BULLFROG AI HOLDINGS, INC. (BFRG) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

0.4 / 5 stars · 2/23 Roast Me

BULLFROG AI HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum

BULLFROG AI HOLDINGS, INC. (BFRG) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.70% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-14

  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.70%, a 7.50% decline year-over-year.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.00%, a 0.00% change year-over-year.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 4.00%.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.70%, a 5.71% increase from fiscal 2024.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.50%, a 2.94% increase from fiscal 2023.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.40%, a 330.38% increase from fiscal 2022.
  • BULLFROG AI HOLDINGS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 0.79%, a 37.30% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month
2026-03-313.70%
10-Q · filed 2026-05-14
2025-12-313.70%
10-K · filed 2026-03-19
2025-09-303.80%
10-Q · filed 2025-11-14
2025-06-304.00%
10-Q · filed 2026-08-14
2025-03-314.00%
10-Q · filed 2026-05-14
2024-12-313.50%
10-K · filed 2026-03-19
2024-09-303.50%
10-Q · filed 2025-11-14
2024-06-304.00%
10-Q · filed 2025-08-13
2024-03-314.00%
10-Q · filed 2025-05-13
2023-12-313.40%
10-K · filed 2025-03-14
2023-09-303.40%
10-Q · filed 2024-11-08
2023-06-303.40%
10-Q · filed 2024-08-07
2022-12-310.79%
10-K · filed 2023-04-25
2021-12-311.26%
10-K · filed 2023-04-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Tempest Therapeutics, Inc. (TPST)United States$0.013B